Diagnosis and management of diabetes-related kidney disease, recognising the effect of multimorbidity, and cardio-renal-metabolic disease

About 40% of people with diabetes will develop chronic kidney disease (CKD), making diabetes the leading cause of CKD. Mortality in people with both diabetes and CKD is higher than in those with either condition alone.

In this episode of the Clinical Update podcast, the MIMS Learning editors look at diabetes-related kidney disease. They discuss the mortality and morbidity associated with the condition, its diagnosis and its management — including the role of SGLT2 inhibitors.

The editors also review what NICE says about glycaemic and lipid targets in this population, noting that glycaemic targets become less strict as CKD progresses.

You can access the website version of this podcast on MIMS Learning to make notes for your appraisal. MIMS Learning offers hundreds of hours of CPD for healthcare professionals, along with a handy CPD organiser.

Please note: this podcast is presented by medical editors and discusses educational content written or presented by doctors, nurses and other healthcare professionals on the MIMS Learning website and at live events.

Further learning on MIMS Learning

Addressing polypharmacy in cardio-renal-metabolic disease

Diabetes-related kidney disease: prevalence, diagnosis, and impact

Diabetes-related kidney disease: five steps to optimise management

Diabetes-related kidney disease: therapy options

Guidance update: latest NICE guidelines on cardiovascular disease risk assessment and reduction

Guidance update: NICE guidelines on chronic kidney disease

MIMS resources

SGLT2 inhibitors for the treatment of type II diabetes

GLP-1 agonists and GIP/GLP-1 agonists for the treatment of type II diabetes

Hosted on Acast. See acast.com/privacy for more information.